Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
rates decrease » rate decreased (Expand Search), greatest decrease (Expand Search), ratio decreased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
rates decrease » rate decreased (Expand Search), greatest decrease (Expand Search), ratio decreased (Expand Search)
-
1401
Changes in the active H3K27ac and repressive H3K27me3 histone marks among Vasa2+/Piwi1+ and all cells in fed, starved, and refed juvenile polyps.
Published 2025“…Between fed, T<sub>5ds</sub> and T<sub>20ds</sub> timepoints, MFI levels of H3K27ac progressively and significantly decreased while levels H3K27me3 (M) did not change significantly (N). …”
-
1402
-
1403
The TOR inhibitors Rapamycin and AZD-8055 strongly reduce RPS6 phosphorylation and cell proliferation in Vasa2+/Piwi1+ cells.
Published 2025“…<i>n</i> = 2–4 biological replicates per condition, with 15 individuals per replicate. Significance levels for Student <i>t</i> test are indicated for adjusted <i>p</i> values: *<i>p</i> < 0.05, ***<i>p</i> < 0.001, ***<i>p</i> < 0.0001. d: day(s), n.s.: non-significant. …”
-
1404
-
1405
-
1406
The age-specific incidence rates of NPC and ENKTL across different time-periods.
Published 2024Subjects: -
1407
Comparison of eye drop instillation success rates across different age groups.
Published 2025Subjects: -
1408
Study Data.
Published 2025“…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”
-
1409
Study outcomes.
Published 2025“…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”
-
1410
Patient characteristics.
Published 2025“…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”
-
1411
-
1412
Expression and diagnostic value of the 8 hub genes in the GSE190635 validation dataset.
Published 2025Subjects: -
1413
-
1414
-
1415
-
1416
-
1417
-
1418
-
1419
-
1420